SCHEMBL166897

SCHEMBL166897

COC(=O)c1cc(C)cc(C(=O)N(C)Cc2ccccn2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ F2 P00734 2/20 0.46
▸ HCRTR1 O43613 1/20 0.45
▸ HCRTR2 O43614 1/20 0.45
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ HIF1A Q16665 1/20 0.41
▸ TRPM8 Q7Z2W7 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ VNN1 O95497 1/20 0.41
▸ GLA P06280 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ PDK1 Q15118 1/20 0.40
▸ PDK2 Q15119 1/20 0.40
▸ PDK3 Q15120 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL166749 0.88 MEN1 (0.51) NPC1RAB9AALDH1A1HCRTR1HCRTR2
SCHEMBL165153 0.86 NPC1 (0.46) NPC1RAB9AALDH1A1F2HCRTR1
SCHEMBL13212689 0.81 VNN1 (0.53) NPC1RAB9AHCRTR1HCRTR2KMT2A
SCHEMBL13211818 0.79 MMP13 (0.51) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL13211426 0.78 KMT2A (0.51) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL167183 0.76 KMT2A (0.58) NPC1RAB9AKMT2AMEN1KDM4E
SCHEMBL453426 0.75 APP (0.49) ALDH1A1KMT2AMEN1KDM4ETDP1
SCHEMBL676887 0.75 SMN1; SMN2 (0.47) NPC1RAB9AALDH1A1KMT2AMEN1
SCHEMBL3508756 0.73 MEN1 (0.49) RAB9AALDH1A1KMT2AMEN1KDM4E
SCHEMBL12459940 0.73 NPC1 (0.49) NPC1RAB9AKMT2AMEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611441-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F.HOFFMANN-LA ROCHE AG (CH) 2013-07-10 — — EP disclosed
WO-2012028563-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-08 — — WO disclosed
WO-2012028563-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-08 — — WO disclosed
US-20120053200-A1 BACE 2 INHIBITORS HOFFMANN-LA ROCHE INC. 2012-03-01 — — US disclosed
US-20120053200-A1 BACE 2 INHIBITORS HOFFMANN-LA ROCHE INC. 2012-03-01 — — US disclosed
US-20120053200-A1 BACE 2 INHIBITORS HOFFMANN-LA ROCHE INC. 2012-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053200-A1 BACE 2 INHIBITORS BACE2, BACE1, PSEN2 NPC1 120/4885RAB9A 3788/4885ALDH1A1 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback